A Phase 2 interventional study of Fulvestrant in Breast Neoplasms, sponsored by AstraZeneca. Completed at 8 sites in 2 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2007-02-09.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 44th largest by enrollment of the 94 interventional ones that give a count, is one of 2 that started in 2000, is one of 59 in phase 2, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 2 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 81st largest by enrollment of the 125 interventional ones that give a count, is one of 2 that started in 2000, is one of 31 in phase 2, and was the 19th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the activity of fulvestrant in postmenopausal women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase inhibitors by estimating the Clinical Benefit Rate
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical Benefit Rate
Duration of clinical benefit
Time to progression
Duration of response
Time to treatment failure
Safety and tolerability
6. clinical benefit rate according to HER2/neu status
This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant